Nearly 66 percent of the genetic mutations that turn into cancer are caused by ‘random replication errors’ during ongoing cell replacement process
Drug-resistant Fungal Infection Reported in More than 30 Cases across United States
More than 30 people across the United States have been diagnosed with Candida auris, a deadly and drug resistant fungal infection, as per CDC report. The authorities had issued first warning regarding Candida auris in June 2016. The drug resistant infection has been noticed in other parts of the world as well.
Candida auris leads to serious bloodstream infections and is communicable. It can survive for month on skin and its traces have been found on bed rails, chairs and hospital equipment for weeks after exposure to infection.
The fungal infection was first reported in Japan in a patient suffering from ear infection. It has also been reported in South Korea, Kenya, United Kingdom, India, Colombia, Kuwait and Israel.
As per CDC data, highest number of infections has been reported in New York. Out of 60 cases in the United States, 28 have been recorded in New York. CDC is keeping a close watch on the infection with regular update on case count. Three cases have been reported in Illinois and 2 in New Jersey.
As per reports, some of the strains of Candida auris are resistant to all three major antifungal drugs. Medical reports suggest that nearly 60 percent of patients suffering from Candida auris don’t survive. However, the reports also suggest that patients suffering from infection had other serious underlying illnesses.
Tom Chiller, the CDC's top fungal expert, "As soon as we put out that alert, we started to get information about cases and now we know more about how it spreads and how it's acting."
Most C. auris infections are treatable with a class of antifungal drugs called echinocandins. However, some C. auris infections have been resistant to all three main classes of antifungal medications, making them more difficult to treat. In this situation, multiple classes of antifungals at high doses may be required to treat the infection.
CDC report on Candida auris further informed…
Candida auris often multidrug-resistant, meaning that it is resistant to most antifungal drugs commonly used to treat Candida infections.
Candida auris is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate treatment.
Candida auris has caused outbreaks in healthcare settings. For this reason, rapid identification of C. auris in a hospitalized patient is particularly important so that hospitals can take special precautions to stop its spread.